(CercleFinance.com) – Innate Pharma announces the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional antibody engaging NK cells (Natural Killer) via NKp46-CD16a and targeting CD123.
‘At Innate Pharma, we are developing a large portfolio of NK cell engagers via our proprietary ANKET platform which can address different types of cancer’, recalls Eric Vivier, scientific director of the biopharmaceutical company.
A phase 1/2 clinical trial, sponsored by Sanofi, evaluating IPH6101/SAR’579 in relapsed or refractory AML, acute lymphoblastic B-cell leukemia or high-risk myelodysplastic syndrome, is also underway.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
